Get the Stockscreener App
19.10
3.29%
-0.65
After Hours:
18.75
-0.35
-1.83%
Cadrenal Therapeutics Inc stock is traded at $19.10, with a volume of 42,544.
It is down -3.29% in the last 24 hours and up +16.75% over the past month.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
See More
Previous Close:
$19.75
Open:
$20.15
24h Volume:
42,544
Relative Volume:
0.65
Market Cap:
$34.05M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-61.61
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
+0.37%
1M Performance:
+16.75%
6M Performance:
+200.53%
1Y Performance:
-4.98%
1-Day Range:
$18.50
$20.49
1-Week Range:
$18.50
$20.49
52-Week Range:
$5.40
$20.79
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
19.10 | 34.05M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics appoints new chief medical officer - MSN
Clinical Trials News Live Feed - StockTitan
Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK
Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - StockTitan
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace
Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan
(CVKD) Investment Report - Stock Traders Daily
Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World
Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals
Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily
Ponte Vedra biotech firm opens the Nasdaq - The Business Journals
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
Cadrenal Therapeutics Advances Tecarfarin Development with FDA Orphan Drug Status and $11.3M Cash Position - StockTitan
AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
(CVKD) Trading Report - Stock Traders Daily
What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World
CVKD: Recent Financings Raise $9.8 Million… - MSN
Kairos Pharma approved to dual list on Upstream - MSN
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - PR Newswire
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):